Panacea Biotec Limited Stock

Equities

PANACEABIO

INE922B01023

Pharmaceuticals

Market Closed - NSE India S.E. 06:14:57 2024-04-25 am EDT 5-day change 1st Jan Change
146.5 INR +3.21% Intraday chart for Panacea Biotec Limited +6.58% -12.75%
Sales 2022 6.61B 79.39M Sales 2023 4.6B 55.23M Capitalization 6.64B 79.76M
Net income 2022 10.78B 129M Net income 2023 -332M -3.99M EV / Sales 2022 0.59 x
Net cash position 2022 5.15B 61.85M Net cash position 2023 1.93B 23.15M EV / Sales 2023 1.02 x
P/E ratio 2022
0.84 x
P/E ratio 2023
-20 x
Employees 1,794
Yield 2022 *
-
Yield 2023
-
Free-Float 20.77%
More Fundamentals * Assessed data
Dynamic Chart
Panacea Biotec Limited Appoints Ambika Sharma as Non-Executive Independent Director CI
Panacea Biotec Limited Announces the Cessation of Mr. Krishna Murari Lal, Mr. Namdeo Narayan Khamitkar and Mr. Raghava Lakshmi Narasimhan as Independent Directors CI
Panacea Biotec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Panacea Biotec Launches EasyFourPol® in India and Receives Registration of Valganciclovir Powder for Oral Solution in Germany CI
Panacea Biotec Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Panacea Biotec Launches Generic Cancer Treatment Drug in Canada MT
Panacea Biotec's Arm Gets Nine Observations from US FDA MT
Indian Immunologicals targets dengue vaccine launch by Jan 2026 RE
Panacea Biotec Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Panacea Biotec Launches New Pediatric Food, Nutritional Products MT
Panacea Biotec Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Panacea Biotec Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Panacea Biotec Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Panacea Biotec Limited Reports Earnings Results for the Nine Months Ended December 31, 2022 CI
Panacea Biotec Donates Pentavalent Vaccine to Cuba MT
More news
1 day+3.21%
1 week+6.58%
Current month+20.53%
1 month+15.90%
3 months-10.29%
6 months-0.81%
Current year-12.75%
More quotes
1 week
134.70
Extreme 134.7
149.90
1 month
120.30
Extreme 120.3
161.25
Current year
120.30
Extreme 120.3
202.50
1 year
114.20
Extreme 114.2
202.50
3 years
107.00
Extreme 107
449.00
5 years
85.95
Extreme 85.95
449.00
10 years
83.70
Extreme 83.7
449.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 84-11-14
Chief Executive Officer 60 84-11-14
Director of Finance/CFO - 15-05-28
Members of the board TitleAgeSince
Chief Executive Officer 60 84-11-14
Chief Executive Officer 58 84-11-14
Director/Board Member 66 16-03-31
More insiders
Date Price Change Volume
24-04-25 146.5 +3.21% 418 127
24-04-24 142 +2.79% 136,774
24-04-23 138.1 +0.07% 66,640
24-04-22 138 +1.17% 72,809
24-04-19 136.4 -0.76% 99,265

Delayed Quote NSE India S.E., April 25, 2024 at 06:14 am EDT

More quotes
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and formulations. It has specialized in the development of fully liquid combination vaccines that can be stored at 2-8 degree Celsius temperature. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRunfull, ChilRun 7+ and ChilRun NoSucrose.
More about the company
  1. Stock Market
  2. Equities
  3. PANACEABIO Stock